Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window:: related changes in susceptibility, resistance frequency and bacterial killing

被引:87
作者
Zinner, SH
Lubenko, IY
Gilbert, D
Simmons, K
Zhao, XL
Drlica, K
Firsov, AA
机构
[1] Gause Inst New Antibiot, Dept Pharmacokinet & Pharmacodynam, Moscow 119021, Russia
[2] Harvard Univ, Sch Med, Mt Auburn Hosp, Dept Med, Cambridge, MA 02138 USA
[3] Roger Williams Med Ctr, Providence, RI USA
[4] Publ Hlth Res Inst, Newark, NJ USA
关键词
MRSA; S; aureus; teicoplanin; vancomycin;
D O I
10.1093/jac/dkg401
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: According to the mutant selection window (MSW) hypothesis, resistant mutants are selected or enriched at antibiotic concentrations above the MIC but below the mutant prevention concentration (MPC). To test this hypothesis, Streptococcus pneumoniae ATCC 49619 (MIC 0.1 mg/L; MPC 0.5 mg/L) was exposed to moxifloxacin concentrations below the MIC, above the MPC and between the MIC and MPC, i.e. within the MSW. Methods: Daily administration of moxifloxacin for 3 consecutive days was mimicked using a two-compartment dynamic model with peripheral units containing a starting inoculum of 10(8) cfu/mL S. pneumoniae. Changes in susceptibility were examined by repeated MIC determinations and by plating the specimens on agar containing zero, 2 x MIC, 4 x MIC and 8 x MIC of moxifloxacin. Results: Both in terms of the MIC and resistance frequency, S. pneumoniae resistance developed at concentrations that fell inside the MSW [ratios of 24 h area under the curve (AUC(24)) to MIC between 24 and 47 h]. A Gaussian-like function fitted the AUC(24)/MIC-dependent increases in MIC and resistance frequency with central points at AUC(24)/MICs of 38 and 42 h, respectively, where resistant mutants are enriched selectively. Selective enrichment of resistant mutants was not seen at AUC(24)/MICs <10 h or >100 h. Conclusions: These data suggest that AUC(24)/MICs >100 h may protect against the selection of resistant S. pneumoniae mutants. Since the usual 400 mg dose of moxifloxacin provides much higher AUC(24)/MIC (270 h), it is expected to prevent mutant selection at clinically achievable concentrations. Also, these data provide further support for the MSW hypothesis.
引用
收藏
页码:616 / 622
页数:7
相关论文
共 20 条
[1]   The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model [J].
Aeschlimann, JR ;
Kaatz, GW ;
Rybak, MJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (03) :343-349
[2]   2 COMPARTMENT KINETIC-MODEL WITH MULTIPLE ARTIFICIAL CAPILLARY UNITS [J].
BLASER, J ;
STONE, BB ;
ZINNER, SH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 15 :131-137
[3]   Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates [J].
Buxbaum, A ;
Straschil, U ;
Moser, C ;
Graninger, W ;
Georgopoulos, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :13-18
[4]   Activities of newer fluoroquinolones against ciprofloxacin resistant Streptococcus pneumoniae [J].
Coyle, EA ;
Kaatz, GW ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1654-1659
[5]   Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: Enzyme activity versus MIC [J].
Firsov, AA ;
Savarino, D ;
Ruble, M ;
Gilbert, D ;
Manzano, B ;
Medeiros, AA ;
Zinner, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :734-738
[6]   AUC/MIC relationships to different endpoints of the antimicrobial effect:: multiple-dose in vitro simulations with moxifloxacin and levofloxacin [J].
Firsov, AA ;
Zinner, SH ;
Vostrov, SN ;
Portnoy, YA ;
Lubenko, IY .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (04) :533-539
[7]   In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus [J].
Firsov, AA ;
Vostrov, SN ;
Lubenko, IY ;
Drlica, K ;
Portnoy, YA ;
Zinner, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1604-1613
[8]   Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model [J].
Klepser, ME ;
Ernst, EJ ;
Petzold, CR ;
Rhomberg, P ;
Doern, GV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :673-678
[9]   Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection [J].
Lacy, MK ;
Lu, W ;
Xu, XW ;
Tessier, PR ;
Nicolau, DP ;
Quintiliani, R ;
Nightingale, CH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (03) :672-677
[10]   Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin [J].
Li, XY ;
Zhao, XL ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :522-524